Considerable research has been conducted into the potential benefits of support groups for patients with metastatic breast cancer. An early report by Spiegel et al. suggested that participation in these groups not only had psychologic benefits but also resulted in prolongation of survival. A review of the published literature was women with metastatic breast cancer who had participated in a randomized trial of group psychosocial support group a decade earlier. These results, which were published in The Lancet, 1 attracted worldwide attention. They proved to be a turning point in psychosocial oncology, opening the door to the possibility of a beneficial survival effect of psychologic interventions in a difficult to treat, and uniformly fatal, oncology setting: metastatic breast cancer. Because the result was unexpected and the study involved only 86 women, members of the scientific community recognized that replication was necessary. However, the results of Spiegel et al. were embraced as conclusive evidence of benefit by many women with breast cancer who were seeking to do everything they could to prolong their survival; by the breast cancer advocacy movement, which was just gaining momentum; and, at times, by members of the clinical and research communities.Survival benefits also have been reported for a brief, individual intervention in a randomized trial in gastrointestinal cancer 2 and a brief group psychosocial intervention in a randomized trial in earlystage melanoma. 3 The latter recently was updated after 10 years of follow-up. 4 The effect of the intervention on recurrence and death was weakened and was not significant in univariate analyses. In 2596